Investor Presentaiton
Research framework in action: anti-CCR8 antibody depletes
T regulatory cells (Tregs) with combination potential
Transformational potential
First-in-class, Treg-depleting monoclonal antibody (mAb)
with broad combo potential across multiple tumor types.
Causal human biology
Clinical trial translational data demonstrate CCR8+ regulatory T
cells (T regs) are a major barrier to effective immune response to
anti-PD1 therapy in multiple cancer types.
Matching modality to mechanism
BMS-986340 is an anti-CCR8 IgG1 biologic with enhanced
non-fucosylated (NF) Fc that binds CCR8 and potently
depletes T regs while sparing effector CD8 T cells.
Path to clinical proof-of-concept
Depletion of CCR8+ Tregs in
the tumor after 2 cycles
Reduced ratio CCR8 Treg to
CD8+ Teff in the tumor
1.5
Anti-PD1
mAb
CCR8
Suppressed
anti-tumor
Tumor cells
survive
response
Activated
CCR8+ Treg
Ill Bristol Myers Squibb™
Т
Suppressed
CD8 T cell
*
Treatment
Screening
CCR8:CD8 ratio
0.5-
1.0.
0.0
Screening
C2D5
Not for Product Promotional Use
26View entire presentation